linjc16/ctgov huggingface dataset:
Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green

Study Overview
=================
Brief Summary
-----------------
This study is exploring whether it's possible to detect paragangliomas (a rare type of tumor) during minimally invasive surgery by using a technique called near-infrared fluorescence imaging, guided by a substance called indocyanine green (ICG). The goal is to see if this method can help surgeons identify and treat paragangliomas more accurately and during minimally invasive procedures.

Official Title
-----------------
Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green

Conditions
-----------------
Paraganglioma

Intervention / Treatment
-----------------
* Drug: Fluorescence guided identification using indocyanine green


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with abdominal paraganglioma and underwent minimally-invasive surgical resection Exclusion Criteria: Open surgical procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective intervention cohort<br> | Drug: Fluorescence guided identification using indocyanine green<br>* During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of real-time in-vivo identification of suspected paraganglioma's using Near-Infrared-fluorescence ICG imaging | The primary outcome of this retrospective study is the ability to visually detect the proportion (%) of suspected pre-operatively identified lesions (paraganglioma) in the abdomen during minimally invasive procedures using Near-Infrared-fluorescence ICG imaging | perioperatively/periprocedurally, within 30 minutes after intravenous administration of the fluorescent dye, up until a maximum of 120 minutes after start of surgery. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of the detection of suspected lesions using Near-Infrared-fluorescence ICG imaging | The secondary outcome of this retrospective study is the accuracy, measured by sensitivity and specificity to identify abdominal paragangliomas using using Near-Infrared-fluorescence ICG imaging | Postoperatively, at the moment the definitive pathology result is known, approximately five days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fluorescence Guided Surgery
Sickle Cell Children's Exercise Study (SuCCESs)

Study Overview
=================
Brief Summary
-----------------
The Sickle Cell Children's Exercise Study (SuCCESs) will explore the feasibility and effects of a moderate intensity strengthening, balance, speed, and agility intervention program in children with sickle cell disease.

Detailed Description
-----------------
Participants will perform the baseline assessment and after six weeks of performing the SuCCESs program the participants will perform a post-intervention assessment. Participants will be asked to attend a total of six physical therapy in-person sessions (1x/week) at the University of Maryland Department of Physical Therapy and Rehabilitation Science and to perform 12 home program sessions.

Official Title
-----------------
Sickle Cell Children's Exercise Study Determining the Effects of a Targeted Exercise Training Program on Neuromuscular Performance, Locomotor Efficiency, and Exercise Tolerance in Children With Sickle Cell Disease.

Conditions
-----------------
Sickle Cell Disease

Intervention / Treatment
-----------------
* Behavioral: SuCCESs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 6-17 years of age diagnosed with sickle cell disease Exclusion Criteria: Diagnosis of neurological disorder, not related to sickle cell disease Lower extremity injury such as a fracture with a cast

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: feasibility study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Physical Therapy Exercise<br>There will be no control group and only one intervention delivered | Behavioral: SuCCESs<br>* strengthening and endurance exercises<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| knee extension strength | dynamometry to measure knee extension strength | week 1 and week 7 | 
| Rate of Muscle Activation | Electromyography used to measure rate of muscle activation | week 1 and week 7 | 
| exercise tolerance | 6-Minute Walk Test used to measure exercise tolerance | week 1 and week 7 | 
| locomotor efficiency | oxygen uptake used to measure locomotor efficiency | week 1 and week 7 | 
| number of sessions attended | attendance | throughout the entire study week 1, weeks 2-6, six weeks of intervention, and week 7 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
physical therapy, neuromotor performance, functional capacity
Developping a a Brain-controlled Art App to Ease Residual Symptoms of Depression

Study Overview
=================
Brief Summary
-----------------
The study evaluate the effect of 10 neurofeedback sessions on the residual symptoms of depressive patients in partial remission.

Official Title
-----------------
Developping a a Brain-controlled Art App to Ease Residual Symptoms of Depression

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Device: Neurofeedback sessions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects aged 25 to 65 included Information and signed informed consent Patients with a diagnosis of major depressive episode in remission MADRS score between 14 and 22 Patients with residual symptoms as assessed by MADRS items No cognitive impairment. Right-handed Exclusion Criteria: Subjects with legal incapacity or limited legal capacity Subjects unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator Pregnant women Subjects in the exclusion period of another study or is on the national volunteer list. Subjects with another psychiatric pathology (bipolar mood disorder, psychosis, obsessive-compulsive disorder, addictive pathology, schizophrenia) Subjects under a protective measure such as guardianship or safeguard of justice.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neurofeedback<br>10 neurofeedback sessions + depressive rating scales | Device: Neurofeedback sessions<br>* 10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the effect of 10 neurofeedback sessions on residual symptoms in depressive patients in partial remission | Reduction in MADRS score to < 8 (complete remission) after 10 neurofeedback sessions, in particular cumulative score less than or equal to 2 for hedonic and fatigue dimensions | Week 10 |
Learning Efficacy and Motivation of Medical Students in Clinical Training With Virtual Reality

Study Overview
=================
Brief Summary
-----------------
We created a curriculum based on clinical events with 360° camera on an interactive learning platform. We hypothesize that medical students will learn better and be motivated with the immersive 360 video and virtual reality headset during the clinical training.

Detailed Description
-----------------
We created a curriculum based on rapid sequence induction before anesthesia induction with 360° camera and put it on an interactive learning platform. We hypothesize that medical students will have better learning efficacy and motivation with the immersive 360 video and virtual reality headset. Moreover, the learning engagement will be translated into clinical skills acquisition and medical knowledge retention.

Official Title
-----------------
Learning Efficacy and Motivation of Medical Students Between Different Teaching Materials and Methods in Clinical Training for Anesthesia and Perioperative Care

Conditions
-----------------
Motivation, Efficacy, Self

Intervention / Treatment
-----------------
* Other: Virtual Reality 360 interactive video
* Other: Traditional mini-lecture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medical students undergoing clinical rotation Exclusion Criteria: Unable to wear virtual reality headset

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Virtual Reality<br>The medical students use the virtual reality headset to watch an interactive 360 video about the clinical situation on the learning platform | Other: Virtual Reality 360 interactive video<br>* Clinical scenarios revised and presented with 360 video, and interactive design on the learning platform that is available anytime and anywhere to the medical students<br>|
| Active Comparator: Traditional<br>The mini-lecture is provided by the instructor to medical students about the clinical situation | Other: Traditional mini-lecture<br>* Clinical scenario described according to the script as a mini-lecture to the medical students<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Learning Efficacy | Learning Efficacy that is assessed by questionnaire | 6 months | 
| Learning Motivation | Learning Motivation that is assessed by questionnaire | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical skills | Clinical skills associated with the clinical scenario that are assessed by simulation on a phantom and checklists | 6 months |
Interstitial Lung Disease Associated

Study Overview
=================
Brief Summary
-----------------
This single-center, retrospective cohort study was conducted to determine whether ANCA-ILD spectrum share the same clinical manifestations and outcome with CTD feature disease spectrum.

Detailed Description
-----------------
We retrospectively reviewed patients who had been diagnosed with interstitial pneumonia during outpatient or hospitalization at Peking Union Medical College Hospital (PUMCH) between January 2012 and December 2021. Baseline data collection: Baseline information at the time of initial diagnosis was obtained, and the following items were analyzed: demographic information (age, gender), clinical course, clinical symptoms and signs, laboratory findings [routine blood, erythrocyte sedimentation rate (ESR), hypersensitivity C-reactive protein (Hs-CRP), rheumatoid factor (RF) and serologic autoantibodies], pulmonary function tests (PFTs), and chest HRCT scans. MPO-ANCA and PR3-ANCA titers were measured by ELISA. Chest HRCT images were evaluated by at least two pulmonologists and radiologists. The HRCT scans were analyzed for the following characteristics: ground-glass opacities, reticular patterns, honeycombing, traction bronchiectasis. Spirometry was performed according to standardized guidelines. PFTs results were expressed as percentages of the predicted values, thereby correcting for age, gender and bodyweight. Treatment was defined as the use of corticosteroids ≥ 10mg/d, azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate, or rituximab. Follow-up was up to the time of patient's last visit or time of death, and the outcomes were defined as death from all causes. Outcome

Official Title
-----------------
Interstitial Lung Disease Associated

Conditions
-----------------
Interstitial Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females Aged from 18 to 85 years with informed consent Have a diagnosis of ILD based on clinical symptoms and radiologic features, with or without histopathologic results Exclusion Criteria: ILD induced by drug, environment, or occupational exposure Hypersensitivity pneumonitis and sarcoidosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | death from all causes | From baseline until the date of death from all cause, up to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Interstitial lung disease, ANCA, CTD, IPAF, IIP
Impact of Lecuofiltration of Packed Red Blood Cells on Different Hematological Parameters Measured by Advia 2120

Study Overview
=================
Brief Summary
-----------------
Parameters of lecuofiltration of packed Red blood cells.

Detailed Description
-----------------
Impact of lecuofiltration of packed Red blood cells on different hematological parameters measured by Advia 2120

Official Title
-----------------
Impact of Lecuofiltration of Packed Red Blood Cells on Different Hematological Parameters Measured by Advia 2120

Conditions
-----------------
Leucodepletion of Packed RBC

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: packed RBC ADIA2120 Exclusion Criteria: Whole blood

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of lecuofiltration of packed Red blood cells on different hematological parameters measured by Advia 2120 | Leucodepletion of packed RBC affects the different parameters of blood component as hemoglobin, platelets , WBCs and so on. Measurement will be done by ADIA2120 hematological analyzer by taking a sample from the packed RBC before and after leucodepletion to compare the difference in hematological parameters. | From 1/1/ 2024 to 29/12/2024 |
The Over The Counter Pill National Study

Study Overview
=================
Brief Summary
-----------------
This is a prospective cohort study of individuals purchasing the oral contraceptive pill over the counter (OTC) in pharmacies in 32 US states. The comparison group is people receiving a prescription (Rx) for oral contraception. Both groups will be followed for one year to examine contraceptive continuation rates. This study will also identify who is using the pill OTC and why and evaluate differences in pregnancy intention and measures of contraceptive agency between the two groups.

Official Title
-----------------
The Over The Counter Pill National Study

Conditions
-----------------
Contraception, Contraception Behavior, Contraceptive Usage, Health Care Utilization

Intervention / Treatment
-----------------
* Other: Availability of OTC contraceptive pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Capable of pregnancy Purchasing oral contraception at a participating pharmacy Exclusion Criteria: Using the pill for non contraceptive indications

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 51 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| OTC users<br>Participants using the oral contraceptive pill purchased over the counter | Other: Availability of OTC contraceptive pill<br>* Over the counter contraceptive pill<br>|
| Rx users<br>Participants using the oral contraceptive pill received by a prescription | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 12 month contraceptive continuation rates | Difference in proportion of participants using contraception 12 months after starting between over the counter and prescription groups. | 12 months |
Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics

Study Overview
=================
Brief Summary
-----------------
Patients referred to internal medicine wards are becoming increasingly complex and fragile. Despite deep knowledge of their specific disorders, steps are required to improve overall management of their acute and chronic conditions. The main objective of the study is to identify demographic, clinical, laboratory and radiological markers of disease severity and activity in patients with diseases treated at general medicine wards (respiratory disease, immune-mediated disease, sepsis, metabolic disease, rare disease, frailty, pregnancy pathology) in order to improve their diagnosis, monitoring and treatment processes.

Official Title
-----------------
Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics

Conditions
-----------------
Respiratory Disease, Cardiovascular Diseases, Infectious Disease, Critical Illness, Immunological Disease, Pregnancy Disease, Metabolic Syndrome, Chronic Disease

Intervention / Treatment
-----------------
* Other: Inpatient or Outpatient visit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Receving treatment at internal medicine departments (inpatient, outopatient, day hospital) of San Raffaele Hospital at least one suspected or confirmed diagnosis among: immune mediated disorder respiratory disorder metabolic disorder sepsis rare disorder (according to Italian Ministry of Health list) pregnancy-related disorder frailty defined as: either ≥2 CIRS (Cumulative Illness Rating Scale) Severity Index 10 or ≤70% Karnofsky scale Exclusion Criteria: refusal to participate enrolment in other intervantional study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases<br>patients treated at internal medicine wards | Other: Inpatient or Outpatient visit<br>* Patients will be seen and treated at the clinics like in the usual care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with severe disease | Identify demographic, clinical, laboratory and radiological markers of disease severity and activity | The following variables will be collected during patient enrollment |
Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to test the effect of nebulized lidocaine on the hemodynamic response in the participant undergoing double-lumen endotracheal intubation. The main question it aims to answer is to evaluate the changes in mean arterial pressure after intubation. Participants will inhale 5ml of 2% lidocaine by nebulization15min before intubation. Researchers will compare saline group to see if saline effects

Official Title
-----------------
Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine: a Randomized, Double-blind, Controlled Trial

Conditions
-----------------
Lung Neoplasms

Intervention / Treatment
-----------------
* Drug: Lidocaine
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18-65 years, American Society of Anesthesiologists class I-II participants undergoing double-lumen endotracheal intubation under general anesthesia signed informed consent and volunteered to participate in the experiment Exclusion Criteria: Poor control of hypertension preoperative arrhythmia severe coronary artery or heart valve disease sequelae of cerebrovascular accident severe lung, liver, kidney and immune system diseases Suspected difficult airway confirmed or suspected allergy to this trial drug As judged by the investigator to be ineligible for the study, such as communication impairment (language or intelligence)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lidocaine<br>Intervention group | Drug: Lidocaine<br>* inhale 5ml of 2% lidocaine by nebulization<br>|
| Placebo Comparator: saline<br>control group | Drug: Saline<br>* inhale 5ml of saline by nebulization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mean arterial pressure after intubation |  | Immediately after intubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Double-lumen Endotracheal Intubation